Clinical Trial of Recombinant Pneumococcal Protein Vaccine
NCT ID: NCT05622942
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2023-03-11
2024-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study was to preliminarily evaluate the safety and immunogenicity of a recombinant pneumococcal protein vaccine applied to adults aged 50 years and older to provide a basis for subsequent clinical trial design.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This clinical trial is a Phase Ib clinical trial in adults aged 50 years and older based on the Phase Ia clinical trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Recombinant Pneumococcal Protein Vaccine（PBPV）
Subjects received 1 dose of PBPV
PBPV
Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Pneumococcal Polysaccharide Vaccine-23-valent (PPV23)
Subjects received 1 dose of PPV23
PPV23
Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PBPV
Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
PPV23
Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to provide legal proof of identity
* Ability to understand the clinical study and voluntarily sign an informed consent form and complete a 6-month follow-up
* Ability to comply with the requirements of the clinical research protocol
Exclusion Criteria
* Positive human immunodeficiency virus (HIV) screening
* History of epilepsy, convulsions or seizures or a history of psychiatric illness or family history
* Received immunosuppressive therapy, cytotoxic therapy, glucocorticoid therapy (excluding topical therapy, surface therapy for acute uncomplicated dermatitis, spray therapy for allergic rhinitis) within the past 6 months (interval \<6 months)
* Suffering from serious chronic diseases or conditions in progress that can't be controlled smoothly, such as serious cardiovascular diseases, chronic hemolytic anemia, thyroid diseases, etc. (except thyroid nodules)
* History of severe anaphylactic reactions (e.g., systemic allergic reactions) to any component of the test drug and/or history of serious adverse reactions associated with other vaccines, such as allergy, urticaria, dyspnea, angioneurotic edema, or abdominal pain
* People with hypertension that cannot be controlled by medication (when measured on site: systolic blood pressure ≥ 160 mmHg, diastolic blood pressure is ≥ 100 mmHg)
* Pre-immune hemoglobin, white blood cell count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatine phosphokinase (CPK), and troponin (CTN) test results are abnormal and are judged by the investigator to be clinically significant
* Positive urine pregnancy test or lactating women, volunteers or their partners planning to become pregnant
* Diseases caused by Streptococcus pneumoniae such as pneumococcal pneumonia, pneumococcal meningitis, etc. within the last 5 years
* Allergic persons, such as those who are allergic to two or more drugs or foods or those who are severely allergic to one drug or food
* Immunocompromised individuals with known or suspected congenital/acquired immunodeficiency as determined by medical history and/or physical examination, uncontrolled autoimmune diseases, etc
* Abnormal coagulation (e.g., clotting factor deficiency, coagulopathy, platelet abnormalities) or significant bruising or clotting disorders
* No spleen or splenectomy due to any condition
* Acute attack of various acute or chronic diseases within the last 7 days
* Pneumococcal vaccination within the last 5 years
* Received or planned to receive blood/plasma products or immunoglobulins during the study period or 3 months prior to vaccination
* Received or plan to participate in an interventional study, receive another investigational drug, vaccine or treatment during the study within the last 1 month
* Received live attenuated vaccine within the last 14 days
* Received subunit vaccine or inactivated vaccine within the last 7 days
* Those planning to have surgery during the study period
* Subject has any other factors that, in the judgment of the investigator, make them unsuitable for participation in the clinical trial
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CanSino Biologics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lancang Lahu Autonomous County Center for Disease Control and Prevention
Puer, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTP-PBPV-002
Identifier Type: -
Identifier Source: org_study_id